https://www.live-feeds.com/feed/updated-electra-says-350m-ipo-will-help-it-become-a-commercial-biotechContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/updated-electra-says-350m-ipo-will-help-it-become-a-commercial-biotechhttps://www.live-feeds.com/feed/updated-electra-says-350m-ipo-will-help-it-become-a-commercial-biotech#u77887Sun, 20 Sep 2026 22:20:07 +0000Electra Therapeutics has priced an upsized initial public offering totaling $350.0 million to transition into a commercial biotechnology company. The immunology drugmaker, which focuses on inflammation, debuted flat on the US market following the pricing. The capital will support the development of ipsoprubart, a late-stage monoclonal antibody targeting secondary hemophagocytic lymphohistiocytosis (sHLH). While the IPO provides significant funding, the company recently faced a going-concern warning from its auditor.Why it mattersThe funding arrives as the biotech IPO window continues to open f